Pancreatic Cancer Has No Reliable Early Detection Test — 5-Year Survival Below 12%

Pancreatic cancer is diagnosed late in >80% of cases because there is no screening test for the general population. 5-year survival is below 12% overall, but screening programs report 24-73% 5-year survival when caught early. A new 4-biomarker blood test (ANPEP, PIGR, CA19-9, THBS2) achieved 91.9% accuracy in a 2026 study.

CA 19-9 is the only FDA-approved pancreatic cancer biomarker but has poor sensitivity (79%) and specificity (82%) for early-stage disease. A February 2026 NIH study identified two new markers — aminopeptidase N (ANPEP) and polymeric immunoglobin receptor (PIGR) — that were elevated in early-stage patients. Combined with CA19-9 and THBS2, the panel distinguished cancer from non-cancer at 91.9% accuracy across all stages. New-onset diabetes after age 50 is emerging as an important risk factor for targeted surveillance. AI-enhanced radiomics on pre-diagnostic CT scans show promise for earlier identification.

Why It Matters

Pancreatic cancer will become the 2nd leading cause of cancer death in the US by 2030. ~64,000 new US cases/year. If detected at Stage I, 5-year survival could reach 44-73%. Current late detection means most patients die within 1-2 years of diagnosis.

Startup Approach

Develop a multi-biomarker blood test combining ANPEP, PIGR, CA19-9, THBS2, and ctDNA for pancreatic cancer screening in high-risk populations (new-onset diabetes >50, family history, chronic pancreatitis). Seek FDA Breakthrough Device designation. Partner with health systems for implementation studies.

NIH Funding

NCI funds pancreatic cancer early detection through EDRN and specialized grants. NIH invested in the ANPEP/PIGR biomarker study. NCI Pancreatic Cancer Detection Consortium.

Who's Working On It

NIH NCI (ANPEP+PIGR biomarker study, Feb 2026), Indiana University (biomarker panel development), Thrive Earlier Detection, GRAIL (methylation-based detection includes pancreatic)